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Glycoprotein gN
Glycoprotein gOCMV, was analysed using real-time quantitative PCR in symptomatic or
asymptomatic pediatric cohorts from HIV-1 infected, exposed (HIV-1+ mothers), or uninfected groups in
Zambia, an HIV-1/AIDS endemic region of Africa. HCMV infections were identiﬁed in 94% samples from
HIV-1+ respiratory pediatric mortalities, 50% with high DNA loads of 103–108 copies/106 cells. In comparison,
HCMV viremia with high DNA loads, indicative of acute infections, were in 10% hospitalised febrile infants,
with 50% HIV-1+. Whereas high sera loads were in 1% of asymptomatic infants, with 2% HIV-1+, and higher
levels in both HIV-1 infected or exposed, but negative infants. All 8 linked-hypervariable glycoprotein gN–gO
genotypes were shown, including identiﬁcation of a new gN4d group with gO5 linkage (previously only
Merlin reference strain), and samples with multiple infections. Overall, this shows global genotypes in Africa
(unlike some herpesviruses) and acute pediatric HCMV infections in both HIV-1+ plus exposed, but
uninfected infants, an emerging group.
© 2008 Elsevier Inc. All rights reserved.Introduction
Human cytomegalovirus, HCMV, causes congenital infections in
neonates and also disease in immunosuppressed transplantation
patients, most severe when linked with pneumonia. In immunosup-
pressed HIV-1/AIDS patients un-treated with anti-retrovirals, HCMV is
the major viral opportunistic infection giving rise to retinitis, as well as
fatal disseminated infections. In healthy immunocompetent individuals
HCMV is rarely pathogenic, and even primary infections in children
appear asymptomatic. However, children who are immunocompro-
mised are at greatest risk, since they can be exposed to primary
infections in the absence of protective immunity. This was demon-
strated in studies in USA predating widespread anti-retrovirals use,
where inHIV-1 infected children, a high prevalence of HCMVcorrelated
withmore severe disease and increasedmortalities (Kovacs et al.,1999).
In Africa, although TB is a well-documented pathogen in pediatric HIV-
1/AIDS, little is known of HCMV in these populations. Furthermore,
while distinct HCMV genotypes have been identiﬁed using hypervari-ompels).
l rights reserved.able glycoprotein genes (Mattick et al., 2004), their overall distribution
in Africa remains undeﬁned. In contrast, some other human herpes-
viruses, HHV-8 and HHV-6, appear to have distinct genotypes and
prevalences present in Africanpopulations (Kakoola et al., 2001; Kasolo
et al., 1997, 1998, 2007; Lacoste et al., 2000; Poole et al., 1999).
Here we analyse HCMV pediatric infections in Zambia, a Southern
African country endemic for HIV-1/AIDS, using qualitative and quanti-
tative PCR, followed by genotyping. Blood or sera samples are compared
from a population based study of asymptomatic infants with sympto-
matic infants hospitalised for febrile disease. These are also compared to
analyses of lung samples from a necropsy study of HIV+ African children
dying from respiratory illness, which had identiﬁedHCMVas a common
infection using immunohistology (Chintu et al., 2002). Here we identify
HCMVDNA present at levels consistentwith viremia in pediatric HIV-1/
AIDS linked respiratorymortalities showing enhanced sensitivity of PCR
(Engelmann et al., 2008;Mattes et al., 2000). Further we also show high
levels in febrileHIV-1+hospitalised infants, aswell asHIV-1 exposedbut
uninfected, fromHIV+mothers, compared toHIV-1negative infants. The
HIV-1 exposed pediatric group is increasing from anti-retroviral
treatment of HIV-1+ mothers at birth, and factors which contribute to
their impaired development are under investigation, such as nutrition,
immunityand infection. Here exposure and levels of a normal childhood
Fig.1.HCMVDNA loads in symptomatic and asymptomatic infants and children. A) Viral
copy numbers were determined by real-time quantitative Taqman PCR for the HCMV gB
gene (Mattes et al., 2005) and then normalised to cell number which was calculated
from cellular genome equivalents determined from Taqman PCR for the human GAPDH
gene (Asahi-Ozaki et al., 2006). Normalised values are given as HCMV copies/106 cells.
(A) HCMV DNA loads are shown for blood samples from the hospitalised febrile infants
and lung samples from HIV-1 positive respiratory mortalities. Median values were
1.2×104 (blood) and 689 (lung) copies/106 cell genome equivalents. (B) HCMV viral
loads in hospitalised and healthy infant cohorts. Median values were 3×105
(hospitalised infants) and 50 (healthy infants, both time points) copies/ml of blood
and sera respectively. For all cohorts: Open triangles=HIV-1 positive infants, closed
triangles=HIV-1 negative infants.
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immunostatus marker, since high plasma levels can be found in
immunosuppressed groups. Moreover, there could be different pre-
valent strains or alteredvirulence. Analyses of hypervariable loci, gNand
gO, showed all gN and gO genotypes previously identiﬁed including
their linkage groups (Mattick et al., 2004; Stanton et al., 2005), and
further identiﬁes a gN4d group previously only represented by the UK
Merlin reference strain, thus deﬁning a new gO5/gN4d linkage group
important for deﬁningbiological differences. Thus, HCMVgenotypes are
distributed worldwide, suggesting similar infections, unlike the
restricted genotypes expressed by human herpesviruses, HHV-6 and
HHV-8. These results suggest a need for HCMV surveillance and
potential for control measures.
Results
Higher HCMV loads in infants from Zambia with HIV-1 infection, either
respiratory disease, or hospitalised for febrile infections, as well as those
with maternal exposure to HIV-1 but remaining HIV-1 negative
The prevalence and relative loads of HCMVDNAwere ﬁrst analysed
in the symptomatic pediatric groups, including retrospective cohorts
of 141 DNA extractedwhole blood samples taken from febrile Zambian
infants aged between 6 and 34 months and 36 DNA extracted lung
biopsies from childhood HIV-1+ respiratory mortalities. Samples were
screened using qualitative and quantitative PCR assays for HCMV gO,
and gB genes (Mattes et al., 2005; Mattick et al., 2004). Table 1 shows
the general prevalence detected. Quantitative PCR was also used to
calculate levels of HCMV (Mattes et al., 2005) relative to levels of
human cellular DNA (GAPDH gene) giving comparative copy number
per cell values as described (Asahi-Ozaki et al., 2006). Fig. 1A shows
such comparisons made between the lung and blood samples giving
high levels comparative to acute febrile infection in a subset of the
respiratory mortality samples. Highest HCMV copy numbers and
prevalence were shown in the HIV-1+ samples with 94% in the lung
and 15% in febrile samples. Lung necropsies could also have blood, but
the overall result show high HCMV levels in these patients.
Next, these results for HCMV linked morbidity samples were
compared to a prospective population based study sampling asymp-
tomatic infant sera at 6 and 18 months age, and comparing HCMV
levels, in HIV-1+, HIV-1 exposed (HIV-1 negative with HIV-1+
mothers) and HIV-1 unexposed, uninfected infants (HIV-1 negative
mothers). Screens by DNA PCR showed HCMV sera DNA prevalence of
9.8% in HIV-1 negative infants, compared to 43% with HIV-1+ infants
at 6 months age (Table 1). Using the GAPDH cellular gene as a marker
for human DNA, the levels of hemolysis could also be determined in
the sera samples as compared to the level of DNA in whole blood,
showing only low levels of hemolysis detected in the sera (b0.01%)Table 1
Percentage HCMV in Zambian children cohorts identiﬁed by DNA PCR
Sample Age HIV-1
positive
HIV-1
negative
Total
Hospitalised illness
Fever (blood,
n= 141)
6–34 months 15%
(7/47)
7.4%
(7/94)
10%
(14/141)
Respiratory (lung,
n= 36)
0–16 years 94.4%
(34/36)
ND 94%
(34/36)
Healthy
Asymptomatic (sera,
n= 180)
6 months 43%
(3/7)a
9.8%
(17/173)a,b
11.1%
(20/180)
Asymptomatic (sera,
n= 203)
18 months 25%
(1/4)
24%
(47/199) b
23.6%
(48/203)
a P= 0.031.
b P= 0.0005.which did not correlate with the different levels of HCMV identiﬁed.
Furthermore, in comparison to prevalence identiﬁed in the HCMV
positive hospitalised fevers, 50% of these are HIV-1+ (7/14), signiﬁ-
cantly greater than those that are asymptomatic which are 15% at
6 months (3/20, P= 0.003) or 2% at 18 months (1/48, P= 0.001).
Although sampling of whole blood compared to sera may be more
sensitive, it is unlikely to account for these differences. Furthermore,
the cut-offs used in the blood sampling are consistent with viremic
levels, not detection of latent DNA, and detection of sera DNA is also
consistent with viremia. Overall HCMV sera DNA prevalence increased
in the asymptomatic groups between 6 and 18 months (9.8% to 24%,
P= 0.0005), consistent with increases in childhood primary infection.
In addition to qualitative detection of sera DNA prevalence,
quantitative analyses of DNA loads were next examined. In the
asymptomatic HCMV positive infants at 6 months, there were
signiﬁcantly higher loads in HIV-1 exposed infants from HIV-1+
mothers, 6/67 (9%), than non-exposed infants from negative mothers,
7/235 (3%), with levels above the threshold of 50 copies/ml up to
Fig. 2. Amino acid alignment of HCMV gO (UL74) genotypes identiﬁes all eight genotype groups. (A) N-terminal (residues 1-148 relative to AD169) for 8 reference sequences with GenBank accession numbers (AD169-gO1a (NP_040008), DM7-
gO1b (AAN40058), Toledo-gO1c (AAN40079.1), PH-gO2a (AC146904) SW1715-gO2b (AAN40066.1), SW475-gO3(AAN40072.1), Towne-gO4 (AAN40080.1) and Merlin-gO5 (YP_081522)) along with representative sequences from blood (K),
lung biopsy (N) and asymptomatic (M6 or M18 sufﬁx) samples. Dots indicate identities relative to prototype AD169 sequences, whereas dashes indicate spaces, differences from representative genotype sequences are in bold. Other sequences,
identical to representative strains shown in the Fig. are as follows: gO1a: AD169 (K60), 40M6 (N6bb, N22bb); gO1b: DM7 (K33, K57, K67, K86, K142), N2a (N9a, N15cc, N18bb, N19a, N23a, N24bb, N25a, N27bb, N34a, N36bb), 35M18 (263M6);
gO1c: Toledo (N31a, N32a); gO2a: N8bb (178M18); gO2b: K61 (N7bb, N10a, N11bb, N21a); gO3: SW475 (N6a, N7a, N8a, N11a, N12a, N17a, N20bb, N26a, N27b, N35bb); gO4: N28a (N33a, N26bb, N28b) and gO5: K141 (N3aa, N13bb, N29b,
N30bb, N35aa, N36a). (B) A 3 frame translation is shown ﬂanking the initiation site in bothMerlin reference strain and Zambian reference g05 genotype K141. A ‘GA’ deletion (underlined) in K141-like sequences introduces a stop codon (⁎) into
frame 1 (dashed line). suggesting internal initiation (solid line, K141).
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Fig. 3. Amino acid alignment of HCMV gN shows seven previously identiﬁed groups and deﬁnes gN4d, the ‘missing’ eighth genotype group. A multiple alignment is shown, using the (UL73) for 7 reference sequences with GenBank accession
numbers as indicated (AD169-gN1 (NP_040007), Can4-gN2 (AAL77764.1), BD-gN3a (AAL77767.1), A8-27F-gN3b (AAO24841.1), Can10-gN4a (AAL77775.1), Towne-gN4b (AAG23510.1), Toledo-gN4c (AAG23509.1)), along with representative
sequences from blood (K) and lung biopsy (N) and asymptomatic (M6 or M18 sufﬁx) samples. (A) Dots indicate identities with respect to AD169 sequence whereas dashes indicate spaces; differences from genotype representative sequences
are in bold. Other sequences, identical to representative strains shown are as follows: gN1: AD169 (N5a, N8c, N17a, N33a, K60, K61, K68, K103, K110, K190, K137); gN2: N7c (N10c); gN3a: BD (263M6, N2b, N9a, N10a, N19a, N23a, N25a, N34a),
K33 (492M6, 503M6,133M18); gN4a: K57 (N6a, N11a); gN4b: N28a (N21a, N27b), and gN4c: Toledo (N31a, N32a). The newly deﬁned gN4d genotype group includes K141 and N18a as shown, plus sample sequences identical to N18a: N1c, N12c,
N20c, N24a, N30a, N36a, and N29a. Merlin is a recently identiﬁed reference strain (Dolan et al., 2004; Stanton et al., 2005) and now groups with this gN4d genotype identiﬁed here. The seven asterisks indicate differences between gN4c and
gN4d.
31
M
.Bates
et
al./
V
irology
382
(2008)
28
–36
32 M. Bates et al. / Virology 382 (2008) 28–365.6×104 copies/ml (P= 0.044). This appeared speciﬁc for HCMV, as was
not shown for related betaherpesvirus, HHV-6. There was little
evidence for persistent viremia and only in the HIV-1+ or exposed
infants. 3/7 HIV-1+ infants were co-infected with HCMV+ (also from
HIV-1+ mothers), and in one of these, where the sample was available
at 18 months, DNAemia was detected at both time points, rising from
210 copies/ml to 793 copies/ml sera at 18 months, although this could
also be a new infection. In the HIV-1 negative asymptomatic samples,
only 3/45 persisted, two at low levels, below the threshold of linear
ampliﬁcation (b50 copies/ml sera) with only one, HIV-1 exposed,
rising to 535 copies at 18 months.
Comparisons were made between DNA loads in the symptomatic
versus asymptomatic cohorts (Fig.1B). Overlapping levels were only at
the top value for one sample in either the 6month or 18-month cohort
at 4.3–5.6×104 copies/ml, and the bottom of the febrile hospitalised
cohort at 1.6×104 copies/ml. The volumes between blood and sera are
two fold concentrated in sera (200 μl sera=400 μl blood), but this
correction still doesn't remove the difference in the medians of the
groups and proportions with high DNA loads. Using similar cut-offs
between the cohorts of 5000 copies/ml for high load acute infections,
there were only 4/302 (1.2%) at 6 months and 2/206 (1%) at 18 months
(median 1×104 copies/ml), whereas in the hospitalised febrile group
10% (14/141) were signiﬁcantly above this cut-off (P= 0.0001),
(median of 3×105 copies/ml) (Fig. 1B). The few higher load values in
the asymptomatic group are consistent with residual primary acute
infections (samples were only taken from healthy recruits). Higher
HCMV sera DNA loads were more common in both the HIV-1+ and
exposed groups.Fig. 4. Phylogenetic analyses of HCMV gN deﬁne gN4d. Relationships are shown using a dista
from blood (K) and lung biopsy (N) and asymptomatic (M6 or M18 sufﬁx) samples, represe
strain (Dolan et al., 2004; Stanton et al., 2005) is again shown grouping with the gN4d genot
strains and representative sequences from this study, using Phylip3.67 software. A distan
defaults) which was then used to generate a phylogeny with ﬁtch.exe (Fitch–Margoliash with
scale represents number of amino acid substitutions per site.All eight HCMV gO and seven gN genotypes, plus an eighth gN4d group
identiﬁed
In the HCMV+ samples, 103 genotypes were analysed. These were
primarily from the symptomatic samples, which had higher DNA
loads. Two loci were analysed, linked-hypervariable glycoprotein
genes gO (UL74) and gN (UL73) which we previously showed having
sufﬁcient variation to detect distinct genotypes, with seven linkage
groups identiﬁed from studies in Australia, Europe and USA (Mattick
et al., 2004; Stanton et al., 2005). An eighth gO genotypewas indicated
by a single USA sample, and later deﬁned by a UK study as gO5, but the
gN linkage was not determined as there was only one gN sequence
from a gO5 genotype isolate, the UK reference strain Merlin (Dolan
et al., 2004; Stanton et al., 2005). This gN sequence was most closely
related to gN4c but diverged at six residues, similar to that between
gN4c with gN4b. Fig. 2A shows all eight gO genotypes identiﬁed in the
Zambian samples (Mattick et al., 2004; Stanton et al., 2005). In
Zambia, gO5 genotypes contained a 2 nucleotide deletion which
caused a frameshift resulting in internal initiation 5 residues down-
stream (Fig. 2B). Fig. 3 shows identiﬁcation of all seven gN genotypes
previously described. In addition, a new eighth group was deﬁned,
gN4d, clustered with the divergent gN from the Merlin strain. In
comparison, the gN4c genotype differs from gN4b at 7 positions.
These gN4d genotypes differed from gN4c at 6 to 7 amino acids and
show a distinct grouping by phylogenetic analyses (Fig. 4). Overall,
there was a similar prevalence of gO and gN genotypes as seen
elsewhere, although in Zambia gO1b and gN3a were more prevalent
(Figs. 5A, B).nce based tree. The seven reference sequences are used as in Fig. 3 along with sequences
nting the genotypes and differences identiﬁed. Merlin the recently identiﬁed reference
ype identiﬁed here as in Fig. 3. The distance tree was generated with the same reference
ce matrix was generated using protdist.exe (Jones-Taylor–Thornton matrix and other
other defaults). The resulting phylogramwas visualized and edited using TreeView. The
Fig. 5. Relative prevalence of HCMV genotypes in Africa is similar to other geographic
regions. (A) gO, (B) gN and (C) linked gO/gN genotypes prevalences in Zambia (black
bars) are compared to those deﬁned previously from Australia, Europe and the USA
(striped bars) (Mattick et al., 2004; Stanton et al., 2005). From Zambia, therewere 62 gO,
56 gN and 52 gO/gN-linked genotypes. From Australia, Europe and USA there were 145
gO, 35 gN and 35 gO/gN-linked genotypes. Published reference strains representing the
8 established linkages were AD169 (gO1a/gN1), M (gO1b/gN3a), ZVs(gO3/gN4a), Toledo
(gO1c/gN4c), Towne(gO4/gN4b), Can4(gO2b/gN2), 1152B(gO2a/gN3b) and now Merlin
(gO5/gN4d). White sections represent sequences derived from Zambian samples for
which triplicate analyses suggested the possibility of multiple infections (see Table 2).
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Analyses of the linkage of the gO and gN genotypes in Fig. 5C show
that they link as previously described (Mattick et al., 2004).
Interestingly, the newly deﬁned gN4d group, linked with the gO5
genotype previously deﬁned in the Merlin strain, thus the missing
eighth gO/gN linkage group (Fig. 5C). The gO1b/gN3a linkage was
most prevalent. Analyses of genotypes available from the asympto-
matic infants, where sufﬁcient sample was available for analyses,
identiﬁed four g01b/gN3a linkages, consistent with the prevalence in
the symptomatic groups. Each PCR reaction was performed indepen-
dently in triplicate, and most samples showed a single gO/gN linkage.
However, a minority of samples, all HIV+ lung samples, with the
exception of those with gO1c/gN4c plus the most prevalent gO1b/
gN3a, also had evidence for multiple infections as indicated in Fig. 5C
and summarised in Table 2. The samples listed had multiple gO,
multiple gN, or both multiple gO and gN genotypes.
Four additional linkages were identiﬁed; these were gO1b/gN1,
gO2b/gN1, gO3/gN4d and gO1b/gN4d. Two of these were previously
identiﬁed in neighboring Malawi (gO1b/gN1 and gO2b/gN1) (Beyari
et al., 2005), and may represent novel linkages present in this region.
With the exception of gO2b/gN1 and gO1b/gN4d in two cases, all
were from samples with evidence of multiple infections; they were
also HIV-1 positive, which may explain the appearance of different
linkages.
Discussion
These results show high levels of HCMV, present within almost all
respiratory and half febrile illness for HIV-1+ infants in Zambia.
Respiratory illness is one of the main causes of mortality in African
children with HIV-1/AIDS under 5 years age (Chintu et al., 2002;
Graham and Gibb, 2002; Walker et al., 2006). Previous results from
immunohistological examinations of Zambian HIV-1+ pediatric
mortalities had shown HCMV was a common infection in infants
under 1 year of age, detected in 42% of the 0–5-month group and 16%
of the 6–11-month group, being the second and third most frequent
opportunistic illness respectively in these patients, and third overall
(22%) for all HIV-1 positive children (Chintu et al., 2002). However,
these results lacked positive identiﬁcation of HCMV using molecular
demonstrations of the virus DNA, further the level or extent of the
infection was uncertain. The results reported here support the
previous HCMV identiﬁcations, but also show, using more sensitive
and quantitative DNA PCR, that HCMV infections are more frequentTable 2
Multiple genotypes detected in HIV-1+ samples1
1 Linked gN/gO genotypes are boxed for reference.
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immunohistological studies (Chintu et al., 2002) and shown more
widely here, HCMV may also underlie further respiratory illness such
as acute pyogenic pneumonia, pneumocystis carini, or TB. Analyses of
respiratory illness in immunosuppressed transplantation patients,
also show that although histology or antigen-based assays such as sera
pp65 antigenemia are speciﬁc, HCMV detection by quantitative PCR is
more sensitive (Engelmann et al., 2008; Mattes et al., 2000).
The population based survey here also showed HCMV sera DNA
detection in asymptomatic HIV-1 negative infants, which may reﬂect
residual primary infectionwithin this group. However these infections
appear subclinical with a median level of 50 copies/ml and do not
correlate with the median level in the hospitalised febrile children
(3×105 copies/ml) or with studies in immunosuppressed transplanta-
tion patients showing high levels of ≥ 104 copies/ml with HCMV
pathology consistent with disseminated or acute infections (Emery
et al., 2000; Gor et al., 1998). Although absolute thresholds are
uncertain and the kinetics of infection can be more informative, these
are signiﬁcant differences. Furthermore, highest loads in this group,
were in both HIV-1+ or HIV-1 exposed groups. Even in the era of
HAART, HCMV viremia can be a marker or determinant of HIV-1/AIDS
progression (Deayton et al., 2004).
This investigation is the ﬁrst molecular demonstration of high
levels (prevalence or quantitative DNA loads) of pediatric HCMV
infections in either HIV-1 infected or exposed groups in this region.
Limited serological and virus culture based analyses of HCMV infected
infants in other African regions suggest infection is earlier than in the
USA or UK. In Gambia, 85% infants under 12 months age were HCMV
infected, as detected by urine culture (Miles et al., 2008, 2007).
However by DNA detection, in USA, 50% HIV-1+ and 25% HIV-1
negative infants were HCMV+, as detected by DNA PCR (Kovacs et al.,
1999), similar to the studies shown here with 43% HIV-1+ at 6 months
and 25% HIV-1 negative infants at 18 months positive for HCMV in
Zambia. Recent immunological analyses of cellular immune responses
to HCMV in Gambian infants, suggest early HCMV stimulation may
provoke immune-dysfunction, as observed in older USA and UK
populations by swamping or skewing the immune system (Miles et al.,
2007). This has been shown to inhibit immunity to some infections
such as inﬂuenza virus vaccine and Epstein-Barr virus (Khan et al.,
2004; Trzonkowski et al., 2003). Interestingly, in other cases such as
measles, it can be immunostimulatory enhancing vaccine efﬁcacy
(Miles et al., 2008). Clearly, for HIV-1, co-infection with HCMV is
grouped with inﬂuenza virus as detrimental. Previous studies in a USA
pediatric HIV-1+ population showed that HCMV enhances progression
to HIV-1/AIDS, increasing mortality, and recent studies suggest HCMV
could be used as a marker or a determinant of progression (Deayton et
al., 2004; Kovacs et al., 1999). The studies presented here suggest
HCMV is also important in African pediatric HIV-1/AIDS respiratory
and febrile illness, either directly or as a co-pathogen.
An important result of these studies is that there are HCMV
infections with high sera DNA loads even in HIV-1 exposed infants
who remain HIV-1 negative despite having HIV-1 positive mothers.
This could be by increased HCMV cervical shedding of the virus or
secretion in the colostrum, as suggested previously for increased
transmission to HIV-1+ infants in USA or for general congenital
infections in the Gambia (Kaye et al., 2008; Kovacs et al., 1999). HIV-1
exposed infants are an expanding group in countries with endemic
HIV/AIDS, given programs for anti-retroviral treatment at birth to
reduce mother-to-child transmission, for example Neviraprine as
given here. Recent studies have shown that such HIV-1 exposed
infants are particularly vulnerable, with impaired development, and
even while remaining HIV-1 free having increased morbidity/
mortality (Makasa et al., 2007; Marinda et al., 2007; Newell et al.,
2004). Factors which contribute to this remain undeﬁned, although
immune suppression in the mother could affect the childrens' health.
Importantly, the results shown here indicate enhanced opportunisticinfections, as demonstrated by increased HCMV levels, may be a key
contributory factor. Studies are ongoing in the 6 and 18-month
cohort study to assess outcomes from other infections and vaccine
effects as well as micro-nutrient interventions to boost development
and immunity to such childhood infections in these HIV-1 exposed
infants. Due to continuing endemic HIV-1 in this region and also to
recently successful measures to reduce mother-to-child transmission
of HIV-1, these exposed but uninfected infants are a key emerging
pediatric patient group in this region and little is known about
factors affecting their poor development. The results shown here
indicate HCMV could be an important marker or cause of morbidity
in this group and the genotypes identiﬁed are global ones rather
than a different strain.
Analyses of some other herpesviruses genotypes, notably Kaposi's
sarcoma associated herpesvirus (HHV-8) or Human herpesvirus 6
(HHV-6), show marked differences in prevalence and type of
genotypes present within African regions (Kasolo et al., 2007; Lacoste
et al., 2000; Poole et al., 1999; Hall et al., 2006; Kasolo et al., 1997). In
contrast, analyses here of HCMV infant infections in Africa, show all
hypervariable glycoprotein genotypes, with similar prevalence to
elsewhere. Minor differences show marginally higher prevalence of
gO1b/gN3a genotypes, in both symptomatic and asymptomatic
groups. Previously, in neighboringMalawi, only two of these genotype
linkages were identiﬁed, gO1a/gN1 and gO1b/gN3a, two of the more
prevalent groups (Beyari et al., 2005). However, only remote family
groups were studied, where there could be isolated genotypes
circulating, whereas the studies presented here are from the central
reference hospital for Zambia. Two additional rare linkages gO1b/gN1
and g02b/gN1 were both in Malawi and the Zambian samples
characterised here. However, this may be from the multiple infections
observed particularly in the HIV-1+ samples.
In contrast to the major differences between genotype groups
(Mattick et al., 2004), within genotype groups there were only minor
coding variations, restricted to 1 to 6 amino acid changes. Thus, similar
to that found previously in other geographic regions, within each
group, there were up to 3% differences, while between the eight
groups, there was 25–55% divergence (Mattick et al., 2004). The
largest change within a genotype was in the gO5 genotype identiﬁed
here which showed evidence for internal initiation, possibly as a
measure to control efﬁciency of expression which could give a
selective advantage in terms of immune presentation. Further, in the
gN2 genotype a two amino acid deletionwas observed, but this was in
the serine/threonine rich domain and may be inﬂuencing reduced O-
linked glycosylation rather than differences in antigenicity. We have
previously shown that these genes are under selective pressure, but
unlike the equally hypervariable HIV-1 gp120, this appears to be
derived from ancient lineages and is currently maintained as
demonstrated by evolutionary modelling from predicted ancestral
genotypes (Mattick et al., 2004). The modelling indicated an ancestral
recombination event drove the selection now evident in the current
genotypes. The data presented here for African samples which show
global genotypes, supports the ancient origin of the HCMV genotypes.
It is not known what constrains these genotypic divisions, but the
linkage with gN suggests a required interaction and also possible
allelic interactions with the host.
Previously, seven gO/gN linkages were described (Mattick et al.,
2004). An eighth gO group was indicated in USA studies where gO
from one sample, 3052 (Rasmussen et al., 2002) did not group with
the others analysed (Mattick et al., 2004). Later a UK study identiﬁed
related examples, designating gO5 (Stanton et al., 2005). The gN was
not analysed for these samples, except in one isolate which is the
reference strain Merlin (Dolan et al., 2004; Stanton et al., 2005). We
have shown here that this gN forms a distinct group, designated
gN4d, which all link with gO5. Thus, now eight gN/gO linkage
groups are shown. The gN and gO genes are encoded in adjacent loci
on the genome, consistent with their observed linkage (Mattick et al.,
35M. Bates et al. / Virology 382 (2008) 28–362004). They also have linked functions in secondary envelopment,
assembly and exit of the virus and antibodies can neutralise
infection suggesting key roles for pathogenicity (Jiang et al., 2008;
Krzyzaniak et al., 2007; Mattick et al., 2004; Paterson et al., 2002;
Rasmussen et al., 2002; Shen et al., 2007). They are amongst a select
subset of hypervariable genes which are suited to following
molecular genotyping, whereas earlier studies using less variable
loci such as gB and gH are more difﬁcult to interpret. In the case of
gH together with gL, these are the conserved partners of a hyper-
variable glycoprotein complex, which combined with gO can
mediate endosomal routes for ﬁbroblast infection (Ryckman et al.,
2008). The gO/gN linkages seem globally maintained, unlike the
bottlenecks apparently applied to infections with KSHV, HHV-6 or
HIV-1 genotypes, and may reﬂect transmission and host interactions
differences. This has implications for global applicability of HCMV
antiviral and vaccine developments. For example, ganciclovir and
the recently available oral prodrug valganciclovir have shown
efﬁcacy against HCMV pediatric infections (Frenkel et al., 2000;
Kimberlin et al., 2008; Wiltshire et al., 2005), and with other
antimicrobials could be considered in management of opportunistic
infections in pediatric HIV-1/AIDS or HIV-1 exposed groups, as well
as new vaccine approaches.
Materials and methods
Patients and samples
The main prospective cohort comprises sera DNA from 302
Zambian infants (paired 6 and 18 months) taking part in CIGNIS
(Chilenje Infant Growth, Nutrition and Infection Study) at Chilenje
suburb local antenatal clinic with support by University Teaching
Hospital, UTH, Lusaka, Zambia. UTH is a 2000-bed referral hospital,
serving approximately 60% of the population. Mother and infant
(18 months, 203) HIV-1 serostatus were also determined. Short
course intrapartum Nevirapine were offered to all HIV-1+ mothers,
according to the local standard of care to reduce mother-to-child
transmission (Chi et al., 2007). Infant groups included HIV-1+ (HIV-1+
with HIV+ mothers), HIV-1 exposed (HIV-1 negative with HIV-1+
mothers), and HIV-1 unexposed, uninfected infants (HIV-1 negative
mothers). For morbidity comparisons, two retrospective UTH
pediatric cohorts were included. The ﬁrst, comprised 141 blood
DNA from infants hospitalised with fever (excluding malaria) as
described (Kasolo et al., 2007). The second cohort was 36 lung tissue
DNA samples from a study of HIV-1+ pediatric respiratory
mortalities (Chintu et al., 2002). Ethical clearance was by the
LSHTM and the joint University Teaching Hospital/University of
Zambia (UTH/UNZA) ethics committees as described (Chintu et al.,
2002; Kasolo et al., 2007). Tissue, blood and sera samples were
stored at −80 °C.
Qualitative and quantitative polymerase chain reaction (PCR)
DNAwas extracted from tissue (∼2 mm2 minced section) or 200 μl
of blood or sera using the QIAamp DNA Blood Mini Kit (Qiagen). DNA
from blood and tissue samples was resuspended in 200 μl, and from
sera in 50 μl. PCRwas used to amplify HCMV glycoprotein gB(UL55) for
qualitative followed by quantitative screens, plus the hypervariable
loci from glycoproteins gN(UL73) and gO(UL74) for subsequent
genotyping through sequence analyses. The human gene, GAPDH,
was used as a control for the DNA extraction protocol and to allow load
comparisons using a quantitative assay for normalisation of viral
relative to cellular DNA levels as described (Asahi-Ozaki et al., 2006) in
the lung tissue and blood samples, and was also used as a control to
measure levels of hemolysis in the sera samples. HCMV DNA copy
numbers were measured on a PRISM® 7000 (Applied Biosystems)
using a Real Time Taqman assay for HCMV gB (primers gB1 and gB2)as described (Mattes et al., 2005). Standard curves were generated
from 10-fold serial dilutions (in triplicate) of DNA standards from
plasmid clones of PCR ampliﬁcation products (TOPO-TA Cloning
Kit, Invitrogen). HCMV gB and GAPDH primers qualitative assays
detected 1 copy/5 μl template. With extraction dilutions, sensitivity
for the blood and sera qualitative assays were 1000 copies/ml and
50 copies/ml respectively. HCMV and GAPDH Real Time assays,
detected 10 and 100 copies/5 μl template, respectively. Genotyping
PCR used nested gN oligonucleotide primers (Sigma Aldrich), gN-Up/
gN-lw (TGGTGTGATGGAGTGGAAC/TAGCCTTTGGTGGTGGTTGC)
internal to U73F/L73R (TTCGGTCGGTCAACATCGTAA/CACCCACGTA-
TGTAAACCTTAC), detecting 1 copy or U73OF/U73OF (CGCGACAGTAC-
CAGTTGAGA/GGGACTATCTAGACTCGCTGCT) detecting 100 copies and
all genotypes. Nested primers for gO were gO-Up/gO-lw (CGACCA-
GAATCAGCAGTGAG/TAGCCTTTGGTGGTGGTTGC), internal to GO1O/
GO2O (CAACGGTAGATGAGCAGCAA/CATGGCGTTAACCAGGTAGAA),
detecting 10 copies and all genotypes. Qualitative PCR reactions
were made up in 25 μl: 12 μl GoTaq® Green Master Mix (Promega),
2.5 μl of each primer (10 μM), 1–5 μl of template DNA made up to 7ul
with dH2O. Thermal cycling parameters were 95 °C for 2 min, then
40× (95 °C 30 s, 59 °C 30 s, 72 °C 2 min) 72 °C for 5 min. Selected
reactions were conﬁrmed using Pfu polymerase. Ampliﬁcation
products were puriﬁed from agarose gels using MinElute Gel
Extraction Kit (QIAGEN). HIV-1 PCR on DNA extracted blood and
tissue samples was carried out as previously (Nanteza et al., 1998). All
PCR assays included both positive and negative controls (including
reagent and water only controls).
Nucleotide sequencing, multiple alignments and phylogenetic analyses
Sequencing reactions were done in 96 well plates for both forward
and reverse strands of PCR products as described (Kasolo et al., 2007),
then run on a 3730 DNA Analyser (Applied Biosystems). Forward and
reverse sequences were edited and compiled using ChromasPro
software, grouped with established genotypes using BLAST (NCBI),
and given GenBank accession numbers EU686416–EU686518. Nucleo-
tide polymorphisms were determined from both strands. Translations
and alignments were analysed using computer software from the
European Molecular Biology Open Software Suite (EMBOSS) plus
Transeq, ClustalW (Chenna et al., 2003; Rice et al., 2000) and Boxshade
(http://www.ch.embnet.org/software/BOX_faq.html). Phylogenetic
analysis used the Phylip3.67 suite of applications (Felsenstein, 1989).
Distance-based phylogenies of alignments were generated with
protdist.exe and ﬁltch.exe and edited in treeview (Page, 1996).
Statistical analyses
Statistical signiﬁcance between groups in cross tabulations was
assessed using Fisher's exact test (Graphpad Prism).
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